Tectonic Therapeutic (NASDAQ:TECX) & CEL-SCI (NYSE:CVM) Head to Head Survey

CEL-SCI (NYSE:CVM) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Profitability

This table compares CEL-SCI and Tectonic Therapeutic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CEL-SCI	N/A	-228.43%	-100.46%
Tectonic Therapeutic	N/A	-35.53%	-31.97%

Risk & Volatility

CEL-SCI has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.63, meaning that its stock price is 163% more volatile than the S&P 500.

Valuation and Earnings

This table compares CEL-SCI and Tectonic Therapeutic”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CEL-SCI	N/A	N/A	-$26.92 million	($0.51)	-0.76
Tectonic Therapeutic	N/A	N/A	$12.16 million	($5.89)	-4.37

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CEL-SCI and Tectonic Therapeutic, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CEL-SCI	0	0	0	0	0.00
Tectonic Therapeutic	0	0	5	1	3.17

Tectonic Therapeutic has a consensus price target of $72.25, indicating a potential upside of 180.91%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than CEL-SCI.

Institutional & Insider Ownership

12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 16.2% of CEL-SCI shares are held by insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Tectonic Therapeutic beats CEL-SCI on 9 of the 12 factors compared between the two stocks.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

About Tectonic Therapeutic

Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.